-
December 17, 2012
GlaxoSmithKline's anthrax treatment raxibacumab has been given the green light by regulators in the USA
Full story
-
July 16, 2012
The rumours were right and GlaxoSmithKline has won the day to acquire Human Genome Sciences, raising its original offer by $1.25 to $14.25 per share.
Full story
-
July 16, 2012
GlaxoSmithKline is expected to announce later today that it has acquired Human Genome Sciences, by offering $200 million more than its previously-rejected $2.60 billion hostile bid
Full story
-
May 10, 2012
GlaxoSmithKline is taking the hostile route in its $2.60 billion bid to buy Human Genome Sciences, going straight to shareholders with its previously-rejected offer instead of participating in the latter's "strategic alternatives review"
Full story
-
April 26, 2012
GlaxoSmithKline has posted first-quarter results which have disappointed analysts and led to a near 3% fall in the UK major's share price
Full story
-
April 19, 2012
Human Genome Sciences has turned down an unsolicited proposal from GlaxoSmithKline, its partner for the lupus drug Benlysta to acquire the firm for $13.00 per share in cash
Full story
-
November 03, 2011
In a landmark decision, the UK's Supreme Court has ruled against Eli Lilly and upheld a patent on a gene sequence held by Human Genome Sciences relating to its new GlaxoSmithKline-partnered lupus drug Benlysta
Full story
-
July 15, 2011
GlaxoSmithKline and Human Genome Sciences' lupus drug Benlysta, which is widely expected to become a blockbuster, has been given the thumbs-up by regulators in Europe
Full story
-
March 11, 2011
Analysts have been reflecting on the US approval granted to Human Genome Sciences and GlaxoSmithKline's lupus drug Benlysta and what it means for patients and the two companies
Full story
-
March 10, 2011
Human Genome Sciences and GlaxoSmithKline are celebrating the news that the US Food and Drug Administration has given the green light to Benlysta, making it the first new treatment to be approved for lupus in 56 years
Full story